Afya Posts 6.1% Q3 Revenue Growth, Margin Up 100 bps, Reaffirms 2026 Guidance
AFYA is trading near its 52-week low of $9.66 (6.9% above the low).
Summary
Afya delivered Q3 2026 revenue of R$985.2 million, up 6.1% year over year, with Adjusted EBITDA up 8.7% to R$433.8 million and margin expanding 100 bps to 44.0%. Net income rose 7.2% to R$171.0 million and basic EPS climbed 10.0% to R$1.88, helped by the buyback. The nine-month picture is softer on profitability: revenue up 6.7% to R$2,970.0 million but Adjusted EBITDA margin down 90 bps to 45.5% as Continuing Education and Medical Practice Solutions absorb investment spending. Management reaffirmed full-year 2026 guidance of R$3,950-4,100 million revenue and R$1,700-1,800 million Adjusted EBITDA. Balance sheet is comfortable — net debt ex-IFRS 16 of R$1,199.8 million, down R$169.7 million from year-end and roughly 0.7x mid-guidance EBITDA, after returning R$459.3 million to shareholders. The Yduqs merger remains the dominant variable; the release confirms the 69%/31% split and that both companies operate independently pending shareholder and antitrust approvals, with a contractual deadline of March 31, 2028.
At the time of this announcement, AFYA was trading at $10.33 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $944.7M. The 52-week trading range was $9.66 to $16.16. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.